ATP-dependent potassium channel agonist; inhibits secretion of insulin from pancreatic beta cells. Prepn: A. A. Rubin et al., Science 133, 2067 (1961); J. G. Topliss et al., US 2986573; eidem, US 3345365 (1961, 1967 both to Schering); Raffa, Monzani, Farmaco Ed. Sci. 17, 244 (1962). Crystal and molecular structure: G. Bandoli, M. Nicolini, J. Cryst. Mol. Struct. 7, 229 (1978). Mechanism of action and metabolism: B. Raju, P. E. Cryer, Am. J. Physiol. Endocrinol. Metab. 288, 80 (2005). Clinical evaluation as an adjuvant in schizophrenia: S. Akhondzadeth et al., J. Clin. Pharm. Ther. 27, 453 (2002); in ischemic preconditioning in coronary artery bypass grafting: X. Wang et al., Eur. J. Cardiothorac. Surg. 24, 967 (2003). Review of effect on insulin secretion: Nutr. Rev. 30, 194-198 (1972); of pharmacology and efficacy in hypertension: J. Koch-Weser, N. Engl. J. Med. 294, 1271-1274 (1976).
Antihypoglycemic; antihypertensive.
Antihypertensive; Thiazides and Analogs; Antihypoglycemic